J Biol Chem, Vol. 274, Issue 35, 25113-25120, August 27, 1999
Hepatocyte Nuclear Factor 3 Relieves Chromatin-mediated
Repression of the
-Fetoprotein Gene*
Alison J.
Crowe
§,
Ling
Sang
,
Kelly Ke
Li¶,
Kathleen C.
Lee
,
Brett T.
Spear¶, and
Michelle C.
Barton
From the
Department of Molecular Genetics,
Biochemistry and Microbiology, University of Cincinnati,
Cincinnati, Ohio 45267-0524 and the ¶ Department of Microbiology
and Immunology, College of Medicine, University of Kentucky,
Lexington, Kentucky 40536-0084
 |
ABSTRACT |
The
-fetoprotein gene (AFP) is tightly
regulated at the tissue-specific level, with expression confined to
endoderm-derived cells. We have reconstituted AFP transcription on
chromatin-assembled DNA templates in vitro. Our studies
show that chromatin assembly is essential for hepatic-specific
expression of the AFP gene. While nucleosome-free AFP DNA is robustly
transcribed in vitro by both cervical (HeLa) and
hepatocellular (HepG2) carcinoma extracts, the general transcription
factors and transactivators present in HeLa extract cannot relieve
chromatin-mediated repression of AFP. In contrast, preincubation with
either HepG2 extract or HeLa extract supplemented with recombinant
hepatocyte nuclear factor 3
(HNF3
), a hepatic-enriched factor
expressed very early during liver development, is sufficient to confer
transcriptional activation on a chromatin-repressed AFP template.
Transient transfection studies illustrate that HNF3
can activate AFP
expression in a non-liver cellular environment, confirming a pivotal
role for HNF3
in establishing hepatic-specific gene expression.
Restriction enzyme accessibility assays reveal that HNF3
promotes
the assembly of an open chromatin structure at the AFP promoter.
Combined, these functional and structural data suggest that chromatin
assembly establishes a barrier to block inappropriate expression of AFP in non-hepatic tissues and that tissue-specific factors, such as
HNF3
, are required to alleviate the chromatin-mediated repression.
 |
INTRODUCTION |
During differentiation, patterns of cell-type specific gene
expression are established which must be maintained throughout the life
of the cell. It is generally assumed that tissue-specific transcription
is achieved through selective synthesis and concentration of cell-type
restricted transcription factors. These regulatory proteins are usually
not as confined in expression as their downstream targets (1, 2).
Additional levels of control in vivo may rely on chromatin
structure that restricts access of ubiquitous or widely expressed
regulatory factors, as well as facilitates synergy between
transcription activators (3, 4). Eukaryotic DNA is highly condensed
into chromatin; this compaction results in a general repression of gene
expression (see Refs. 5 and 6, and reviewed in Ref. 7). Nuclease
sensitivity mapping of a number of genes has indicated a clear pattern
of accessible chromatin structure around actively transcribing genes
during development (2, 8-13). The chicken
-globin locus, for
example, is maintained in a DNase I-sensitive chromatin structure in
erythroid cells, whereas this region is inaccessible to enzyme
digestion in non-erythroid cells (14). The
A globin
promoter acquires an open chromatin conformation only at the onset of
expression in definitive red blood cells (13, 14). Thus,
tissue-specific and developmental expression patterns are accompanied
by distinct alterations in chromatin structure.
The liver tumor marker gene,
-fetoprotein
(AFP),1 displays strict
tissue-specific and developmental regulation in vivo
(reviewed in Refs. 15 and 16). AFP is highly expressed during fetal development in endoderm-derived tissues including the yolk sac, liver,
and gut. At birth, unlike other liver-specific genes, AFP expression is
rapidly repressed (17) and is only reactivated in cases of renewed
cellular proliferation, including liver regeneration and hepatocellular
carcinoma (17, 18). Differential AFP expression patterns are
accompanied by discrete changes in local chromatin structure as
measured by DNase I hypersensitivity (reviewed in Refs. 15 and 19-21).
AFP thus provides an excellent model to assay the potential
contribution of chromatin structure to tissue-specific gene regulation.
Previous studies using transient transfections and transgenic mice have
identified multiple regulatory elements that control AFP expression.
These include three distinct enhancers and a promoter/repressor region
(19, 20, 22, 23). The enhancers were found to activate a heterologous
promoter in non-hepatic cells, while a 1-kilobase fragment containing
only the distal and proximal promoter regions exhibited absolute tissue
specificity (19). The AFP promoter from
1 kb to the start site is
therefore a major determinant of liver-specific transcription. Several
liver-enriched proteins which direct hepatocyte-specific expression
have been shown to bind multiple sites within the AFP promoter
(reviewed in Ref. 24), including CAAT/enhancer-binding protein (25),
hepatocyte nuclear factor 1 (HNF1; 26), and hepatocyte nuclear factor 3 (HNF3; 27). The HNF3 family is composed of three members, HNF3
,
HNF3
, and HNF3
, which, along with the Drosophila fork
head protein, constitute a growing family of winged-helix
DNA-binding proteins (28). HNF3/fork head proteins that regulate gene
expression in endoderm-derived tissues are required for pattern
formation in the embryonic gut (see Ref. 29, reviewed in Ref. 30).
HNF3
is of particular interest as it has been shown to position
nucleosomes within the enhancer of the liver-specific albumin gene (31, 32). A role for HNF3 in organizing chromatin is further supported by
the three-dimensional structural similarity of the winged helix conformation to the globular domain of linker histones (33, 34);
functional conservation of this domain was confirmed by studies
demonstrating the nucleosome-binding properties of HNF3 (35). However,
the mechanism by which HNF3 transactivates hepatic-specific genes
remains unclear.
We show here that in vitro reconstitution of AFP expression
patterns requires both activating and repressive influences. In order
to model the tissue-specific expression of the AFP gene, we have used
Xenopus laevis egg extracts as a source of histones and
nucleosome assembly factors that can reconstitute physiologically spaced nucleosomes in vitro. Our results indicate that the
general repressive nature of nucleosomal DNA is necessary to restrict transcription factor access in a non-hepatic environment. Transcription activation, within the context of chromatin, is achieved by binding of
hepatic-enriched factors that mediate the restructuring of chromatin
into a transcriptionally competent form. Furthermore, we find that
HNF3
, in the absence of other hepatic-specific factors, is capable
of activating AFP transcription both in vitro and in vivo, demonstrating a critical role for this fork head
homolog in programming liver-specific expression patterns.
 |
EXPERIMENTAL PROCEDURES |
Plasmids and Generation of AFP/Bead DNA Templates--
The
AFP(1.0)-lacZ vector was constructed by replacing the 177-bp
BamHI-HindIII fragment of
(pA)3-AP
44-lacZ (36) with a 1.0-kb
BamHI-HindIII fragment containing the AFP
promoter/repressor region. The AFP(3.8)-lacZ vector was
generated by inserting a 2.8-kb BamHI fragment containing
AFP enhancer element I into the BamHI site of
AFP(1.0)-lacZ. The HNF3
and HNF3
eukaryotic expression vector(s) were a kind gift from Dr. Robert Costa.
The HNF3 empty vector was generated by removing the entire
HNF3
cDNA insert from the HNF3
vector.
The HNF3
bacterial expression vector was kindly provided by Dr.
Kenneth Zaret.
To obtain immobilized templates, AFP(1.0)-lacZ and
AFP(3.8)-lacZ were digested with EcoRI and
ClaI. The resulting fragments were Klenow end-filled with
biotin 21-dUTP (CLONTECH) and biotin 14-dATP (Life
Technologies, Inc.) to generate uniquely biotin-labeled EcoRI sites. Unincorporated nucleotides and small fragments
were removed by gel filtration (Chromaspin 1000, CLONTECH). The largest 9.0-kb fragment encompassing
the AFP enhancer I and promoter sequences were coupled to
streptavidin-coated paramagnetic beads (Dynal) in Kilobase Binding
Buffer (Dynal) on a rotating platform at room temperature overnight
exactly as described by the manufacturer. Coupled beads were washed 3 times with 2 M NaCl, TE, pH 8.0, and stored in
phosphate-buffered saline at 4 °C until use.
Transfections--
HeLa and HepG2 cells were transfected with an
AFP reporter construct (AFP(1.0)-lacZ) and either an
HNF3 empty vector or an HNF3 expression vector
along with a CAT control vector using the calcium phosphate protocol as
described (36). Forty-eight hours after transfection, cells were
harvested.
-Galactosidase assays were performed as described
previously (36) and normalized to CAT activity to control for
variations in transfection.
Protein Extracts--
Hepatocarcinoma cell extracts were
prepared from human HepG2 cells according to the method of Dignam
et al. (37) with the following minor modifications. Cells
were grown to 70% confluence and harvested by scraping into
phosphate-buffered saline. Washed pellets were resuspended in hypotonic
buffer (20 mM HEPES, pH 7.9, 10 mM NaCl, 1.5 mM MgCl2, 2 mM dithiothreitol).
After swelling 10 min on ice, cells were pelleted and resuspended in
hypotonic buffer containing 0.05% Nonidet P-40 prior to Dounce
homogenization (Wheaton, type B). Protein extracts were dialyzed
against 2 changes of nuclear dialysis buffer (NDB: 20 mM
HEPES, pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20%
glycerol, 1 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride) for 2 h. each. Final protein
concentration ranged from 7 to 12 µg/µl. HeLa nuclear extract was
prepared exactly as described in Current Protocols in Molecular Biology
(38). Final protein concentration ranged from 8 to 10 µg/µl.
Xenopus egg chromatin assembly extracts were prepared
exactly as described previously (39). Final protein concentrations
ranged from 40 to 60 µg/µl. Recombinant HNF3
protein was
expressed in Escherichia coli and purified exactly as
described previously (40). Final protein concentration was
approximately 150 ng/µl.
In Vitro Transcription Reactions--
Prior to nucleosome
assembly, immobilized AFP templates were preincubated for 20 min at
room temperature with the indicated extracts or NDB. Xenopus
egg cytoplasmic fraction (HSS) in an amount previously determined to
fully repress transcription was added to assemble the bead-DNA into
chromatin for 1 h at 22 °C. Prior to transcription, the
assembled templates were washed 3 times in NDB (unless otherwise
indicated). Washed templates were then in vitro transcribed
upon addition of an RNA polymerase II-containing nuclear HeLa extract
(37) and an NTP/salts/energy-generating mixture to give final
concentrations of 0.6 mM CTP, UTP, GTP, ATP, 5 mM MgCl2, 50 mM KCl, 5 mM creatine phosphate, 10 units/ml of creatine kinase,
0.02% Nonidet P-40 (Sigma), and 12.6 mM HEPES, pH 7.9. After a 60-min incubation at 30 °C, RNA products were purified and
analyzed by primer extension and gel electrophoresis (41).
Micrococcal Nuclease Analysis--
Nucleosome assembly on the
AFP/bead DNA was assessed by micrococcal nuclease (Roche Molecular
Biochemicals) digestion after a 2-h incubation at 22 °C with
fractionated Xenopus egg extract HSS containing 3 mM ATP and 5 mM MgCl2. Samples were
digested and analyzed exactly as described previously (42).
Chromatin Structure Analysis--
AFP bead/DNA was assembled
into chromatin under conditions exactly as described for in
vitro transcription analysis and then subjected to restriction
enzyme digestion. Chromatin-assembled bead/DNA was washed once in
1 × React 2 restriction enzyme buffer (50 mM Tris-Cl,
pH 8.0, 10 mM MgCl2, 50 mM NaCl;
Life Technologies, Inc.) prior to resuspension in the same buffer
containing HincII (Life Technologies, Inc.) at 25 units/µg
of DNA. Following a 30-min incubation at 37 °C, samples were
digested with 1 mg/ml proteinase K (Life Technologies, Inc.) in 0.25%
SDS, 12.5 mM EDTA, pH 8.0, for 1 h at 37 °C. For
the HincII fragment release assay (Fig. 5A), the
purified DNA was resuspended in agarose gel loading dye and samples
were analyzed by Southern blot as described previously (42). A 23-bp
probe (+5 to +28) was used to detect the 84-bp released fragment (
55
to +29). To measure accessibility at the distal HincII site
(Fig. 5B), the purified DNA was resuspended in 1 × React 1 restriction enzyme buffer (50 mM Tris-Cl, pH 8.0, 10 mM MgCl2; Life Technologies, Inc.) and
digested to completion with 5 units of AccI (Life
Technologies, Inc.). Digested samples were analyzed by Southern blot
using a 24-bp probe (+3333 to +3356) to detect a 4.0-kb
Eco/HincII fragment. Autoradiograms were scanned and
quantified using ImageQuaNT (Molecular Dynamics, version 4.2) software.
For the HincII fragment release assay, activation over a
buffer preincubated control was determined for three independent experiments and the average fold activation (± S.E.) was determined after normalizing to the buffer control. To determine the percent accessibility at the distal HincII site, we divided the
intensity of the 4.0 kb released fragment by the sum of the 6.4-kb
parent band and the released fragment. The fold activation was
determined after normalizing to the buffer control.
Analysis of Start Complex Stability--
AFP bead/DNA was mock
chromatin-assembled by preincubation with protein extracts in the
presence or absence of recombinant HNF3
(750 ng) for 20 min prior to
a 60-min incubation in egg extract buffer (100 mM KCl, 4 mM MgCl2, 10 mM HEPES, pH 7.2, 100 mM sucrose, 0.1 mM EGTA) ± 3 mM ATP. Assembled bead/DNA was washed 3 times in NDB
containing 0.5% Nonidet P-40, and then incubated in an
NTP/salts/energy-generating mixture to give final concentrations of 0.6 mM CTP, UTP, GTP, ATP, 5 mM MgCl2,
50 mM KCl, 5 mM creatine phosphate, 10 units/ml
of creatine kinase, 0.02% Nonidet P-40 (Sigma) and 12.6 mM
HEPES, pH 7.9. After a 60-min incubation at 30 °C, RNA products were
purified and analyzed by primer extension and gel electrophoresis
(41).
 |
RESULTS |
In Vitro Transcription of AFP Does Not Recapitulate Tissue-specific
Expression Patterns in the Absence of Chromatin Structure--
To
explore the basis for tissue-specific AFP regulation, we have employed
an in vitro transcription system for AFP. The well characterized human hepatoma cell line HepG2 (43) was used as a source
of AFP trans-activating factors. Human cervical carcinoma HeLa cells
were chosen as a source of non-liver transcription factors. HepG2 cells
actively express both endogenous and transiently introduced AFP,
whereas HeLa cells do not (19). To establish an in vitro
chromatin transcription assay for the AFP gene, we have attached AFP
DNA to streptavidin-coated paramagnetic beads. This system, based on a
design for transcriptional analysis of the Drosophila hsp70
promoter (44), facilitates the rapid purification and concentration of
chromatin-assembled templates. A plasmid containing 3.8 kb of mouse AFP
regulatory sequence (AFP(3.8)-lacZ), including enhancer I
and the distal and proximal promoter elements (36), was restriction
enzyme-digested, biotin-end labeled and coupled to streptavidin-coated
magnetic beads. The immobilized DNA (AFP/bead DNA) was then transcribed
under standard in vitro transcription conditions with either
HeLa or HepG2 extract (Fig. 1).
Nucleosome-free AFP/bead DNA is efficiently transcribed by both
extracts, with peak transcription occurring in the presence of 15 µl
of extract, each containing approximately 150 µg of total protein
(lanes 3 and 6). These results indicate that restrictions required to
direct tissue-specific expression of AFP in vivo cannot be
recapitulated on free DNA.

View larger version (80K):
[in this window]
[in a new window]
|
Fig. 1.
In vitro transcription of AFP in
both HeLa and HepG2 extracts. Biotin end-labeled AFP template
coupled to magnetic beads was in vitro transcribed either in
the absence of extract (lane 1), or in the presence of HeLa
nuclear extract (lanes 2-4) or HepG2 extract (lanes
5-7) in amounts of 10 µl (lanes 2 and 5),
15 µl (lanes 3 and 6), or 20 µl (lanes
4 and 7). Transcripts were detected by primer
extension. The 84-bp AFP primer extension product is indicated by an
arrow. Radiolabeled X 174 DNA digested with
HaeIII (Life Technologies, Inc.) was used as a molecular
weight marker (MW).
|
|
Solid-phase Chromatin Assembly--
To recreate in
vitro the physiological constraints conferred by chromatin
in vivo, AFP/bead DNA was subjected to nucleosome assembly.
Chromatin assembly was achieved by incubation with fractionated Xenopus egg extract. The cytoplasmic fraction or high speed
supernatant (HSS) of Xenopus eggs efficiently assembles
physiologically spaced nucleosomes (45) and has been used in previous
chromatin transcription studies (42, 46). Efficiency of chromatin
assembly was assessed by micrococcal nuclease digestion. A time course
of digestion with micrococcal nuclease indicated the formation of a
repetitive array of nucleosomes on the bead/DNA (Fig.
2A). This pattern is identical
to that observed on uncoupled AFP DNA incubated in Xenopus HSS (data not shown). We further assessed the extent of chromatin assembly by measuring transcription levels. Assembly of AFP/bead DNA
into nucleosomes in the presence of HSS resulted in repression of AFP
transcription (Fig. 2B, compare lanes 1 and
2). This transcriptional repression was maintained during
washes in a low salt (50 mM KCl) buffer. However,
repression was alleviated by washing the chromatin-assembled bead/DNA
in a high salt (3 M KCl) wash buffer (lane 3).
As 3 M KCl is a sufficiently high salt concentration to
disrupt histone/histone and histone/DNA interactions, these data
suggest that the repression of AFP transcription observed in lane
2 is mediated by nucleosome assembly. Together, these results
indicate that AFP/bead DNA is efficiently assembled into nucleosomal
DNA in the presence of Xenopus egg extract.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleosome assembly on immobilized AFP
templates. A, chromatin structure of immobilized AFP
template. Immobilized AFP DNA was nucleosome-assembled in fractionated
Xenopus egg extract for 2 h. Chromatin-assembled DNA
was digested with micrococcal nuclease (MNase) and one-tenth
volume aliquots were withdrawn for analysis at the following times: 0, 10, 20, 40, 60, and 80 min. Nucleosome spacing was estimated by
comparison to a 123-bp DNA ladder (Life Technologies, Inc.). Mono-,
di-, and trinucleosomes are indicated by arrows.
B, nucleosome assembly represses transcription of AFP in
HeLa extracts. Immobilized AFP DNA was incubated in NDB alone
(lane 1), or in cytoplasmic Xenopus egg extract
(Xl HSS) for 1 h (lanes 2 and 3). Templates
were washed 3 times with either NDB (50 mM KCl; lanes
1 and 2) or with high salt NDB (3 M KCl;
lane 3). Washed templates were transcribed in
vitro in an RNA polymerase II-containing HeLa nuclear extract.
Transcripts were detected by primer extension.
|
|
Hepatoma-specific Derepression of Chromatin-assembled AFP
Templates--
As shown above (Fig. 1), HepG2 and HeLa extracts
transcribe naked AFP DNA templates in vitro with equal
efficiencies. To determine whether these transcriptionally competent
extracts were capable of establishing active transcription on a
chromatin-assembled template, AFP/bead DNA was incubated with
increasing amounts of either HeLa or HepG2 extracts or in nuclear
extract buffer alone prior to chromatin assembly (Fig.
3). This "programming" phase allows
transactivators and repressors to bind their respective sites on the
nucleosome-free template prior to reconstitution into chromatin.
Nucleosome-assembled templates, programmed in this way, were washed in
low salt buffer prior to transcription to remove any unassociated
proteins and nonspecific transcription repressors; this washing step
further ensures that only DNA-associated proteins and protein complexes
are present during the in vitro transcription analysis.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 3.
Hepatoma-specific derepression of nucleosome
assembled AFP DNA. A, hepatoma-specific factors
establish transcriptionally active chromatin templates. Immobilized AFP
templates were incubated with NDB (lane 1), or increasing
amounts of either HeLa nuclear extract (lanes 2-4) or HepG2
extract (lanes 5-7) prior to a 1-h chromatin assembly in
fractionated Xenopus egg extract (Xl HSS).
Amounts of nuclear extract added during preincubation were as follows:
5 µl (approximately 50 µg of total protein; lanes 2 and
5), 10 µl (approximately 100 µg of total protein;
lanes 3 and 6), and 20 µl (approximately 200 µg of total protein; lanes 4 and 7).
Chromatin-assembled templates were washed in nuclear extract buffer and
transcribed in vitro in an RNA polymerase II-containing HeLa
nuclear extract. B, AFP enhancer element I is not required
for hepatoma-mediated derepression. Immobilized AFP templates which
contained (lanes 1-5) or lacked enhancer I (lanes
6-9) were incubated with NDB (lanes 1, 3, 6, and
9), HeLa (lane 5), or hepatoma extract
(lanes 2, 4, 7, and 9), either prior to
(lanes 1, 2, 5, 6, and 7) or during (lanes
3, 4, 8, and 9) chromatin assembly. Chromatin-assembled
templates were processed as in A. The AFP primer extension
product is indicated by an arrow. C,
preincubation with cellular extracts does not disrupt nucleosome
assembly. Immobilized AFP DNA was incubated in NDB (lanes
1-3 and 10-12), HepG2 extract (lanes 4-6
and 13-15), or HeLa extract (lanes 7-9 and
16-18) prior to chromatin assembly in fractionated Xl HSS
under transcription conditions. Nucleosome-assembled templates were
subjected to digestion with micrococcal nuclease for 60 min
(lanes 2, 5, 8, 11, 14, and 17), 120 min
(lanes 3, 6, 9, 12, 15, and 18) or left
undigested (lanes 1, 4, 7, 10, 13, and 16).
Samples were analyzed by Southern analysis using either a
transcriptional start site probe (lanes 1-9) or a
full-length AFP(3.8)-lacZ probe (lanes 10-18).
Mononucleosomes are indicated by an arrow. A 123-bp ladder
(Life Technologies, Inc.) was used as a molecular weight marker
(horizontal lines).
|
|
Chromatin-mediated repression could not be alleviated by providing HeLa
factors prior to nucleosome assembly (Fig. 3A, compare lanes 1 and 2-4). Thus, general transcription
factors and non-hepatic transactivators provided by the HeLa extract
are insufficient to mediate assembly of a chromatin template which
supports transcription. In contrast, incubating AFP/bead DNA with HepG2
extract during the programming stage, prior to nucleosome assembly,
resulted in transcriptionally active templates (lanes 5-7).
Comparison with a nucleosome-free AFP template control transcription
(data not shown) revealed that the HepG2 preincubation rescued 90%
(±3.9% S.E.) of free DNA transcription levels, indicating almost
complete derepression of the chromatin template. An equivalent level of derepression was obtained when hepatoma factors were introduced concomitant with egg extract addition (Fig. 3B, compare
lanes 2 and 4, 7 and 9). Hepatoma
factors can, therefore, successfully compete with histones to bind
their respective sites during on-going chromatin assembly and
maturation. Addition of a low salt wash step immediately after
pre-binding of the hepatoma extract did not significantly alter
hepatoma-mediated assembly into an active chromatin template,
indicating the stability of the protein/DNA interactions (data not
shown). To confirm that preincubation with cellular extract under
transcription conditions did not disrupt nucleosome assembly, chromatin
templates preincubated with buffer, HepG2, or HeLa extract were
subjected to a limit digest with micrococcal nuclease (Fig.
3C). Southern analysis of the digested DNA was performed
using either a transcriptional start site oligo (+5 to +28) or the
full-length AFP(3.8)-lacZ plasmid as a probe. Equivalent amounts of mononucleosomes were observed under all three transcription conditions, indicating that HepG2-mediated transcription activation was
not due to gross inhibition of nucleosome assembly.
Nucleosome-free AFP templates which lack the enhancer element but
retain 1.0 kb of upstream regulatory sequence
(AFP(1.0)-lacZ), are transcribed as efficiently as the
full-length enhancer-containing construct (AFP(3.8)-lacZ) in
in vitro transcription assays with nuclear HeLa extract
(data not shown). Transcription analysis of chromatin-assembled
templates indicates that the enhancer is not required to establish
hepatoma-activated AFP expression in vitro (Fig. 3B,
lanes 6-9). These results indicate that 1.0 kb of AFP upstream
regulatory sequence is sufficient to confer liver-specific expression,
consistent with previous transfection studies by Tilghman and
colleagues (19).
These data demonstrate that HepG2 extract contains factors which are
capable of stably associating with AFP regulatory sequences and
directing the assembly of an accessible chromatin structure. HeLa
extract is unable to program transcriptionally competent nucleosome-assembled DNA, indicating either a lack of essential activators or the presence of repressors which only function within the
context of chromatin. Thus, our in vitro chromatin
transcription assay system successfully recapitulates the restricted
AFP expression pattern observed in vivo, indicating the
importance of chromatin structure for tissue-specific regulation of
AFP. These results along with the robust transcription of
nucleosome-free AFP DNA observed in HeLa extract (Fig. 1), suggest that
hepatic-specific factors may enhance the formation of functional
preinitiation complexes on the nucleosome-assembled AFP template.
HNF3 Alleviates Chromatin Repression--
One likely candidate for
such an hepatic-enriched factor is the winged helix protein, HNF3,
which regulates the transcription of numerous liver-specific genes
including albumin, transthyretin, and phosphoenolpyruvate carboxykinase
(reviewed in Refs. 30 and 47). HNF3
has recently been found to
modulate chromatin structure at the albumin enhancer and thereby
promote subsequent binding of additional transactivators (31, 35). The
AFP proximal and distal promoter regions contain three HNF3-binding
sites (27).2 Transient
transfection experiments have demonstrated that HNF3
activates AFP
expression (this work and Ref. 27). To directly determine the mechanism
of HNF3
-mediated activation, immobilized templates were incubated
with increasing amounts of recombinant HNF3
protein in the presence
of HeLa extract prior to chromatin assembly (Fig.
4A). Co-incubation with HeLa
extract and HNF3
(750 ng) is sufficient to reconstitute 30-40% of
the activation achieved on HepG2-assembled chromatin DNA (lanes
4 and 5). As HNF3 expression is restricted to
endodermal-derived tissues such as liver, HeLa cells lack this critical
hepatic factor (48). Preincubation with HNF3
alone is insufficient
to activate transcription of chromatin-assembled DNA (data not shown),
indicating that HNF3-mediated relief of chromatin repression requires
the presence of HeLa nuclear proteins. The inability of HNF3
to
reconstitute 100% of the crude HepG2 extract activity may indicate
that other liver-specific factors are required for optimal AFP
expression.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
HNF3 activates AFP transcription in the
absence of other hepatic factors. A, HNF3 alleviates
chromatin-mediated repression in vitro. Immobilized
templates were preincubated with NDB (lane 1), hepatoma
extract (lane 2), or HeLa extract (lanes 3-5)
supplemented with recombinant HNF3 protein (450 ng, lane
4; 750 ng, lane 5). Templates were chromatin assembled
and processed as described in the legend to Fig. 3. B, HNF3
transactivates AFP in HeLa cells. HeLa and HepG2 cells were transfected
with AFP(1.0)-lacZ, HNF3 , or
HNF3 expression vectors, and a CAT control vector. Cells
were harvested 24 h after transfection and cell lysates were
analyzed for -galactosidase ( -gal) activity.
-Galactosidase activity was normalized to CAT activity to control
for variations in transfection efficiency.
|
|
HNF3 Activates AFP Expression in HeLa Cells--
To confirm
HNF3-mediated activation of AFP expression in a non-hepatic environment
in vivo, transient transfection experiments were performed.
Although transiently transfected DNA does not appear to assemble the
same higher-order chromatin structure observed with genomic DNA,
certain aspects of nucleosome-mediated regulation can be observed on
transiently expressed DNA (reviewed in Ref. 49). HeLa cells were
co-transfected with an AFP(1.0)-lacZ reporter construct,
which lacks AFP enhancer elements, along with either an
HNF3
or HNF3
expression vector. The AFP
promoter exhibits very low levels of activity upon transfection into
HeLa cells (Fig. 4B). The lack of AFP promoter activity in
HeLa cells in the absence of hepatic-enriched factors is consistent
with previous studies in HeLa cells (19) and supports our assumption
that some level of nucleosome assembly is occurring on the introduced plasmid, resulting in transcription repression. In contrast,
transfection of the AFP(1.0)-lacZ reporter construct into
HepG2 cells results in high levels of
-galactosidase activity, as
expected due to the presence of HNF3 and other hepatic activators.
Co-transfection of the AFP reporter into HeLa cells with an HNF3
expression vector resulted in strong activation of AFP expression.
Comparison of
-galactosidase activity between cell lines revealed
that HNF3
-transfected HeLa cells displayed approximately 55% of the
activity obtained from transfection of AFP(1.0)-lacZ into
HepG2 cells, in close agreement with the level of HNF3 activation
observed on in vitro chromatin templates (Fig.
4A). HNF3
and HNF3
were equally capable of activating
the AFP promoter, suggesting that there are no differences in the
ability of these factors to bind putative sites in this region. We have
not yet determined whether HNF3
functions similarly to HNF3
in
in vitro chromatin reconstitution experiments. These results
illustrate the ability of our in vitro system to identify physiologically relevant regulators of tissue-specific gene expression. Furthermore, the cell culture demonstration of HNF3-induced AFP activation in a non-liver cell confirms the pivotal role HNF3 plays in
establishing hepatic-specific expression.
Stability of Preinitiation Complexes under Chromatin Assembly
Conditions--
In order to promote physiological nucleosome spacing,
our in vitro chromatin assembly reactions are performed in
the presence of 3 mM ATP and 5 mM
MgCl2 (50). As high concentrations of ATP have been found
to affect the stability of preinitiation complexes (PICs) (51-54), it
was possible that the tissue-specific expression patterns achieved upon
chromatin assembly reflected a differential sensitivity of PIC
formation and/or stability to ATP. To assay PIC response to ATP, we
performed mock chromatin assembly reactions in the presence or absence
of 3 mM ATP. Normal in vitro transcription conditions were restored by washing and resuspending the DNA templates in transcription reaction mixture lacking additional nuclear extract. Transcription from existing PICs was initiated by addition of 0.6 mM NTPs. As shown in Fig. 5,
preincubation with either HeLa or HepG2 extract in the absence of ATP
generated stable PICs capable of robust transcription (Fig. 5,
lanes 3 and 7). Incubation with ATP resulted in
destabilization of both HeLa (5.5-fold repressed) and HepG2 (12.3-fold
repressed) extract-generated PICs (compare lanes 3 and
4, and lanes 7 and 8), indicating that
the tissue-specific expression observed under chromatin assembly
conditions was not the result of differential ATP-dependent
inhibition. Indeed, transcription complexes assembled by the hepatoma
extract were more sensitive to ATP incubation conditions than HeLa
PICs.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
Preinitiation complex stability.
Immobilized AFP templates were preincubated with NDB (lanes
1 and 2), HeLa extract (lanes 3 and
4), HeLa extract supplemented with 750 ng of HNF3
(lanes 5 and 6), or HepG2 extract (lanes
7 and 8) prior to mock chromatin assembly for 1 h
either in the presence (lanes 2, 4, 6, and 8) or
absence (lanes 1, 3, 5, and 7) of ATP.
Transcription was initiated from stable start complexes by the addition
of NTPs. Transcripts were detected by primer extension. Radiolabeled
X 174 DNA digested with HaeIII (Life Technologies, Inc.)
was used as a molecular weight marker (MW).
|
|
Supplementing HeLa extract with recombinant HNF3
prior to mock
chromatin assembly had only a negligible effect in the absence of ATP
(compare lanes 3 and 5), but stimulated
transcription 2.5-fold under ATP conditions (compare lanes 4 and 6). Comparison of ATP inhibition of HeLa transcription
in the presence and absence of HNF3 (lanes 4 and
6) reveals an intriguing role for HNF3 in stabilizing start
complexes. HNF3 partially protects the established PICs from
ATP-dependent disruption, and may therefore contribute to hepatic-specific expression by enhancing the stability of PICs. This
level of activation is approximately 30% of that obtained in the
presence of chromatin (8.7-fold; see Fig. 4A), indicating that a chromatin context is required to achieve full HNF3-mediated transactivation.
HNF3
-mediated Changes in Chromatin
Structure--
Transcriptionally active chromatin templates can
frequently be distinguished from their inactive counterparts by
analysis of chromatin structure (reviewed in Refs. 55-57). Inactive
chromatin generally exists in a "closed" or inaccessible form as
measured by both nuclease and restriction enzyme digestion, whereas
active chromatin is predominantly in a more accessible state. HNF3 has been shown to position nucleosomes over the albumin gene enhancer (31,
35). Therefore, we examined whether this transactivator could alter
chromatin structure at the AFP promoter. Our structural analysis
focused on the 1.0-kb sequence immediately upstream of the AFP
transcriptional start site as this region has been shown to direct
tissue-specific expression of AFP both in vitro and in
tissue culture cells (this work and see Ref. 19). HincII restriction enzyme recognition sites flank the AFP transcriptional start site (
55 and +29 bp), resulting in the release of an 84-bp fragment if both sites are accessible. A fragment release assay allows
us to determine the relative accessibility of this region in
chromatin-assembled templates.
As shown in Fig. 6, recombinant HNF3
significantly increased restriction enzyme accessibility in this
region. Unprogrammed chromatin templates (buffer only) are refractory
to digestion (Fig. 6A, lane 2). Programming with HeLa
extract enhanced accessibility 4-fold over buffer alone (Fig. 6,
A, lane 4, and C), possibly due to the formation
of non-functional preinitiation complexes. Addition of HNF3 protein
alone resulted in 6-fold enhanced accessibility (Fig. 6, A, lane
6, and C), suggesting that HNF3 may function on its own
at some level to relieve chromatin repression. Chromatin remodeling by
HNF3 alone may be mediated through site-specific binding to one or more
of the three putative promoter-binding sites, two of which lie within
200 bp of the transcriptional start site. Co-incubation with HNF3 and
HeLa extract resulted in an additive increase (10-fold) in
accessibility (Fig. 6A, lane 8, and C),
indicating that factors in the HeLa extract enhance HNF3s ability to
establish an "open" promoter structure. To determine whether the
HNF3 protein was nonspecifically inhibiting chromatin assembly on the
AFP template, we assayed accessibility at a distal HincII
site, which lies within vector sequence 4.0 kb upstream of the
transcriptional start site. Restriction enzyme analysis of chromatin
templates, assembled under identical conditions to those in Fig.
6A, revealed no significant increase in distal site accessibility in the presence of HNF3 and/or HeLa extract when compared
with a buffer control (Fig. 6, B and C).
Furthermore, a comparison of micrococcal nuclease limit digests
performed on chromatin templates preincubated with either HeLa extract
(Fig. 3C) or recombinant HNF3
in HeLa extract (data not
shown) showed no global disruption of nucleosome assembly in the
presence of HNF3. These studies indicate the presence of localized,
tissue-specific structural changes that correlate with enhanced
transcription activity. Furthermore, these data suggest a critical role
for hepatic-specific factors, such as HNF3, in generating discrete alterations in chromatin structure that are required for AFP expression in hepatocytes.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
HNF3 alters chromatin structure.
A, HNF3 enhances restriction enzyme accessibility at the AFP
transcriptional start site. Immobilized AFP templates were preincubated
with NDB (lanes 1 and 2), HeLa extract
(lanes 3 and 4), 750 ng of recombinant HNF3
(lanes 5 and 6), or HeLa extract supplemented
with 750 ng of HNF3 (lanes 7 and 8) prior to
chromatin assembly for 1.5 h in fractionated Xenopus
egg extract. After chromatin assembly, templates were either left
undigested (lanes 1, 3, 5, and 7) or digested
with HincII (lanes 2, 4, 6, and 8) for
30 min at 37 °C (25 units of HincII/µg of DNA). DNA was
purified and subjected to electrophoresis followed by Southern analysis
with an oligo probe which recognizes the 84-bp released
HincII fragment ( 55 to +29 bp) indicated by an
arrow. The location of restriction sites and probe sequences
are depicted in the lower diagram (A, AccI;
C, ClaI; E, EcoRI;
H, HincII). The transcription start site is
indicated by an arrow. The paramagnetic bead is indicated by
a sphere. B, HNF3 does not alter accessibility at
a distal site. Immobilized AFP templates were preincubated and
assembled exactly as described in A. Following
HincII digestion, purified DNA was digested to completion
with AccI. Southern analysis was performed using an oligo
probe that recognizes a 4.0-kb EcoRI/HincII
fragment along with the 6.4-kb EcoRI/AccI parent
band. Abbreviations and symbols are as described in
A. C, quantitation of restriction enzyme
accessibility. Autoradiograms were scanned and quantified using
ImageQuaNT (Molecular Dynamics, version 4.2) software. Black
bars indicate HincII accessibility at the AFP
transcription start site. Gray bars indicate accessibility
at the distal site. In both cases, the buffer-assembled control was
normalized to 1 and the average fold activation over control is shown.
Values for promoter accessibility were averaged from three independent
experiments (± S.E.).
|
|
 |
DISCUSSION |
The ability to accurately assay transactivator function in
vitro depends upon reconstitution of both the constraints and
enhancements placed on a gene in vivo. As many activators
and repressors display widely varying affinities for nucleosomal
versus free DNA, it has become increasingly clear that gene
regulation must be analyzed within the context of chromatin. General
transcription factors and transactivators present in HeLa extract are
capable of efficiently transcribing naked AFP DNA templates, but are
unable to interact productively with chromatin-repressed templates and
are also insufficient to establish a transcriptionally competent
template when provided prior to chromatin assembly. These results are
in direct contrast to those obtained using the adenovirus major late
promoter as a DNA template (58, 59). HeLa extract efficiently
establishes transcriptionally competent adenovirus templates, both on
nucleosome-free DNA and when incubated prior to nucleosome
reconstitution. The inability of HeLa extract to activate
chromatin-reconstituted AFP templates may illustrate the higher level
of restriction placed on a tissue-specific cellular gene compared with
the relatively promiscuous expression of a viral gene. Tissue-specific
activators, such as HNF3, may be required to properly position
nucleosomes and recruit RNA polymerase II complexes to the AFP
promoter. In contrast, HeLa-induced activation of nucleosome-assembled
adenovirus major late promoter may reflect general promoter derepression.
Chromatin structure has been implicated in developmental and
tissue-specific regulation of a number of genes (reviewed in Ref. 60).
Alterations in chromatin structure of both plant and animal genes have
long been known to correlate with changes in gene expression (13,
61-65). Although tissue-specific transactivators and chromatin
remodelers (66, 67) have been described, our in vitro
analysis of the AFP gene provides the first demonstration of an RNA
polymerase II-transcribed animal gene whose tissue-specific expression
pattern is imposed by chromatin structure itself. To our knowledge, the
only other example of chromatin structure dictating tissue specificity
comes from the plant storage protein gene,
-phaseolin, in which
rotational positioning of a nucleosome over the TATA region in
nonexpressing vegetative tissues blocks
-phaseolin transcription at
the level of initiation (68). Thus, tissue-restricted gene expression
is likely the result of highly regulated derepression of chromatin by
cell type-specific chromatin modulators.
Numerous studies have demonstrated that while increased chromatin
accessibility generally precedes transcription activation, structural
changes alone are often insufficient to confer gene activation
(reviewed in Refs. 69 and 70). Analysis of the Xenopus
TR
A promoter (71) and the human immunodeficiency virus-1 promoter
(72) reveal that nucleosomal disruption and gene activation are
separable events, suggesting that chromatin remodeling is just one in a
series of steps which lead to transcription activation. Our data
indicate that the structural changes mediated by preincubation with
either HeLa extract or HNF3
alone are not sufficient for AFP
activation. However, the enhanced accessibility that accompanies co-incubation with HNF3
and HeLa extract correlates with
transcription activation. Additionally, HNF3 may perform a role in
derepression of HeLa-programmed templates that must precede AFP
activation, such as recruitment or stabilizing general transcription
factor interaction with the promoter.
The stability of functional PICs on naked DNA templates is greatly
inhibited in the presence of ATP. Previous reports have revealed a role
for the ATPase Mot1p in Saccharomyces cerevisiae and its
closely related mammalian homologue TAFII172/170 in
ATP-dependent inhibition of transcription (52, 53, 73). In
the presence of ATP, these SNF2 family members inhibit TBP-driven
in vitro transcription by dissociating TBP from DNA, but
exhibit little or no effect on TFIID complexes (52). In vivo
analysis of Mot1p action in yeast has shown that this essential protein
can act as both a corepressor (74) and an activator of specific gene expression (75-77), possibly by releasing free TBP from nonpromoter sites. The inhibition of PIC formation in our studies implies either a
surprisingly high ratio of TBP versus TFIID-driven
transcription in crude nuclear extracts or, alternatively, the presence
of a previously uncharacterized ATP-dependent inhibition
function. Our results support: 1) a diminished role for general
transcription factors in establishing active chromatin on complex
promoters; and/or 2) formation of chromatin that stabilizes PIC
assembly in the presence of tissue-specific activator(s). Upstream
activators, such as HNF3 (this study) or Gal4p-VP16 (52), may act in
recruiting general transcription factors, stabilizing PIC formation,
and thereby preventing ATP-dependent inhibition. However,
we find that the majority of tissue specificity relies on chromatin
structure activation: HNF3 plays a 3-fold greater role in transcription activation of chromatin (8.7-fold) than chromatin-free (2.5-fold) DNA
templates under the same incubation conditions.
As chromatin structure is required to restrict access of non-hepatic
factors, we reasoned that "loosening" of HeLa-assembled chromatin
templates through hyperacetylation might be sufficient to relieve
repression. To this end, we reconstituted immobilized AFP DNA
preincubated with HeLa extract into nucleosomes by supplying Xenopus extract which had been preincubated with increasing
amounts of the histone deacetylase inhibitor, trichostatin A (78). Even at micromolar concentrations, this inhibitor had no alleviating effect
on chromatin-mediated repression (data not shown), suggesting that
hepatoma-specific factors must also be present either to stabilize the
accessible chromatin structure or to recruit the general
transcription machinery to the chromatin-assembled templates.
A role for HNF3 in establishing a transcriptionally accessible
chromatin structure is well supported by structural analysis of the
evolutionarily related albumin gene. These studies found that HNF3
binding is required for nucleosome positioning over the albumin
enhancer (31, 32), consistent with the hepatic-specific expression
pattern observed for albumin in vivo. HNF3, which
structurally resembles linker histone H5 (34), can bind in place of a
linker histone molecule to a degenerate HNF3-binding site on the side of a core nucleosome, but lacks the basic amino acids present in linker
histones required to mediate compaction of nucleosomal DNA (35). Our
in vitro analysis of HNF3 provides the first demonstration that HNF3-directed structural changes functionally mediate derepression of transcription on a chromatin template. Combined, these data suggest
a mechanism by which HNF3 potentiates the assembly of a
transcriptionally competent chromatin structure poised for expression.
The studies presented here demonstrate that chromatin structure is
required to impose tissue-specific regulation on the AFP gene in
vitro and describe a role for HNF3 as a cell-type specific chromatin modulator. Our results suggest two, non-exclusive, mechanisms for HNF3-mediated derepression: 1) HNF3-specific disruption of a
TBP-associating negative cofactor and 2) HNF3-directed chromatin remodeling of the AFP promoter region. Future studies will attempt to
differentiate between these two possibilities by examining the cascade
of events initiated by HNF3 binding which leads to localized
perturbation of chromatin structure and enhanced transcription.
 |
ACKNOWLEDGEMENTS |
We thank K. Zaret for the HNF3
expression vector and purification protocol and R. Costa for the
HNF3 mammalian expression vectors. We are also grateful to
I. Cartwright, L. Pile, and J. Ma for helpful discussions and comments
on the manuscript. Additionally, we acknowledge reviewer comments that
helped in the completion of this work.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants GM53683 (to M. C. B.) and GM45253 (to B. T. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of National Research Service Award postdoctoral
fellowship CA73083.
Recipient of an American Cancer Society Junior Faculty Award
JFRA-610. To whom correspondence should be addressed. Tel.:
513558-5541; Fax: 513-558-8474; E-mail:
Michelle.Barton@uc.edu.
2
B. Spear, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
AFP,
-fetoprotein;
kb, kilobase(s);
HNF, hepatocyte nuclear factor;
bp, base pair(s);
CAT, chloramphenicol acetyltransferase;
HSS, high speed
supernatant;
PIC, preinitiation complex.
 |
REFERENCES |
| 1.
|
Graef, I.,
and Crabtree, G.
(1997)
Science
277,
193-194[Free Full Text]
|
| 2.
|
Henderson, A. J.,
and Calame, K. L.
(1995)
Crit. Rev. Eukaryotic Gene Expression
5,
255-280[Medline]
[Order article via Infotrieve]
|
| 3.
|
Naar, A. M.,
Beurang, P. A.,
Robinson, K. M.,
Oliner, J. D.,
Avizonis, D.,
Scheek, S.,
Zwicker, J.,
Kadonaga, J. T.,
and Tjian, R.
(1998)
Genes Dev.
12,
3020-3031[Abstract/Free Full Text]
|
| 4.
|
Adams, C. C.,
and Workman, J. L.
(1995)
Mol. Cell. Biol.
15,
1405-1421[Abstract]
|
| 5.
|
Felsenfeld, G.
(1992)
Nature
355,
219-224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Knezetic, J. A.,
and Luse, D. S.
(1986)
Cell
45,
95-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Wolffe, A. P.
(1990)
New Biol.
2,
211-218[Medline]
[Order article via Infotrieve]
|
| 8.
|
Aronow, B. J.,
Ebert, C. A.,
Valerius, M. T.,
Potter, S. S.,
Wiginton, D. A.,
Witte, D. P.,
and Hutton, J. J.
(1995)
Mol. Cell. Biol.
15,
1123-1135[Abstract]
|
| 9.
|
Asenbauer, H.,
and Klobeck, H. G.
(1996)
Eur. J. Immunol.
26,
142-150[Medline]
[Order article via Infotrieve]
|
| 10.
|
Jones, B. K.,
Monks, B. R.,
Liebhaber, S. A.,
and Cooke, N. E.
(1995)
Mol. Cell. Biol.
15,
7010-7021[Abstract]
|
| 11.
|
McGhee, J. D.,
Wood, W. I.,
Dolan, M.,
Engel, J. D.,
and Felsenfeld, G.
(1981)
Cell
27,
45-55[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Nickel, B. E.,
and Cattini, P. A.
(1996)
Mol. Cell. Endocrinol.
118,
155-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Stadler, J.,
Larsen, A.,
Engel, J. D.,
Dolan, M.,
Groudine, M.,
and Weintraub, H.
(1980)
Cell
20,
451-460[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Reitman, M.,
and Felsenfeld, G.
(1990)
Mol. Cell. Biol.
10,
2774-2786[Abstract/Free Full Text]
|
| 15.
|
Camper, S. A.,
Godbout, R.,
and Tilghman, S. M.
(1989)
Prog. Nucleic Acids Res. Mol. Biol.
36,
131-143[Medline]
[Order article via Infotrieve]
|
| 16.
|
Nahon, J.-L.
(1987)
Biochimie (Paris)
69,
445-459[Medline]
[Order article via Infotrieve]
|
| 17.
|
Tilghman, S. M.
(1985)
Oxf. Surv. Eukaryotic Genes
2,
160-206[Medline]
[Order article via Infotrieve]
|
| 18.
|
Nakabayashi, H.,
Hashimoto, T.,
Miyao, Y.,
Tjong, K. K.,
Chan, J.,
and Tamaoki, T.
(1991)
Mol. Cell. Biol.
11,
5885-5893[Abstract/Free Full Text]
|
| 19.
|
Godbout, R.,
Ingram, R.,
and Tilghman, S. M.
(1986)
Mol. Cell. Biol.
6,
477-487[Abstract/Free Full Text]
|
| 20.
|
Godbout, R.,
Ingram, R. S.,
and Tilghman, S. M.
(1988)
Mol. Cell. Biol.
8,
1169-1178[Abstract/Free Full Text]
|
| 21.
|
Godbout, R.,
and Tilghman, S. M.
(1988)
Genes Dev.
2,
949-956[Abstract/Free Full Text]
|
| 22.
|
Hammer, R. E.,
Krumlauf, R.,
Camper, S. A.,
Brinster, R. L.,
and Tilghman, S. M.
(1987)
Science
235,
53-58[Abstract/Free Full Text]
|
| 23.
|
Vacher, J.,
and Tilghman, S. M.
(1990)
Science
250,
1732-1735[Abstract/Free Full Text]
|
| 24.
|
Cereghini, S.
(1996)
FASEB J.
10,
267-282[Abstract]
|
| 25.
|
Zhang, D.-E.,
Hoyt, P. R.,
and Papaconstantinou, J.
(1990)
J. Biol. Chem.
265,
3382-3391[Abstract/Free Full Text]
|
| 26.
|
Feuerman, M. H.,
Godbout, R.,
Ingram, R. S.,
and Tilghman, S. M.
(1989)
Mol. Cell. Biol.
9,
4204-4212[Abstract/Free Full Text]
|
| 27.
|
Lee, K. C.,
Crowe, A. J.,
and Barton, M. C.
(1999)
Mol. Cell. Biol.
19,
1279-1288[Abstract/Free Full Text]
|
| 28.
|
Lai, E.,
Prezioso, V. R.,
Tao, W.,
Chen, W. S.,
and Darnell, J. E. J.
(1991)
Genes Dev.
5,
416-427[Abstract/Free Full Text]
|
| 29.
|
Dufort, D.,
Schwartz, L.,
Harpal, K.,
and Rossant, J.
(1998)
Development
125,
3015-3025[Abstract]
|
| 30.
|
Kaufmann, E.,
and Knochel, W.
(1996)
Mech. Dev.
57,
3-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
McPherson, C. E.,
Eun-Yong, S.,
Friedman, D. S.,
and Zaret, K. S.
(1993)
Cell
75,
387-398[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Shim, E. Y.,
Woodcock, C.,
and Zaret, K. S.
(1998)
Genes Dev.
12,
5-10[Abstract/Free Full Text]
|
| 33.
|
Clark, K. L.,
Halay, E. D.,
Lai, E.,
and Burley, S. K.
(1993)
Nature
364,
412-420[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Goytisolo, F. A.,
Gerchman, S. E., Yu, X.,
Rees, C.,
Graziano, V.,
Ramakrishnan, V.,
and Thomas, J. O.
(1996)
EMBO J.
15,
3421-3429[Medline]
[Order article via Infotrieve]
|
| 35.
|
Cirillo, L. A.,
McPherson, C. E.,
Bossard, P.,
Stevens, K.,
Cherian, S.,
Yon Shim, E.,
Clark, K. L.,
Burley, S. K.,
and Zaret, K. S.
(1998)
EMBO J.
17,
244-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Spear, B. T.,
Longley, T.,
Moulder, S.,
Wang, S. L.,
and Peterson, M. L.
(1995)
DNA Cell Biol.
14,
635-642[Medline]
[Order article via Infotrieve]
|
| 37.
|
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 38.
| Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987)
Current Protocols in Molecular Biology (Janssen, K., ed)
1st Ed., Current Protocols, Boston
|
| 39.
|
Barton, M. C.,
and Emerson, B. M.
(1996)
Methods Enzymol.
274,
299-312[Medline]
[Order article via Infotrieve]
|
| 40.
|
Zaret, K. S.,
and Stevens, K.
(1995)
Protein Expression Purif.
6,
821-825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Waterman, M. L.,
Fischer, W. H.,
and Jones, K. A.
(1991)
Genes Dev.
5,
656-669[Abstract/Free Full Text]
|
| 42.
|
Barton, M. C.,
Madani, N.,
and Emerson, B. M.
(1993)
Genes Dev.
7,
1796-1809[Abstract/Free Full Text]
|
| 43.
|
Aden, D. P.,
Fogel, A.,
Plotkin, S.,
Damjanov, I.,
and Knowles, B. B.
(1979)
Nature
282,
615-618[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Sandaltzopoulos, R.,
Blank, T.,
and Becker, P. B.
(1994)
EMBO J.
13,
373-379[Medline]
[Order article via Infotrieve]
|
| 45.
|
Rhodes, D.,
and Laskey, R. A.
(1989)
Methods Enzymol.
170,
575-585[Medline]
[Order article via Infotrieve]
|
| 46.
|
Barton, M. C.,
and Emerson, B. M.
(1994)
Genes Dev.
8,
2453-2465[Abstract/Free Full Text]
|
| 47.
|
Vallet, V.,
Benedicte, A.,
Chafey, P.,
Vandewalle, A.,
and Kahn, A.
(1995)
Mol. Cell. Biol.
15,
5453-5460[Abstract]
|
| 48.
|
Pani, L.,
Qian, X.,
Clevidence, D.,
and Costa, R.
(1992)
Mol. Cell. Biol.
12,
552-562[Abstract/Free Full Text]
|
| 49.
|
Smith, C. L.,
and Hager, G. L.
(1997)
J. Biol. Chem.
272,
27493-28496[Free Full Text]
|
| 50.
|
Almouzni, G.,
Mechali, M.,
and Wolffe, A. P.
(1991)
Mol. Cell. Biol.
11,
655-665[Abstract/Free Full Text]
|
| 51.
|
Cai, H.,
and Luse, D. S.
(1987)
Mol. Cell. Biol.
7,
3371-3379[Abstract/Free Full Text]
|
| 52.
|
Auble, D. T.,
Hansen, K. E.,
Mueller, C. G.,
Lane, W. S.,
Thorner, J.,
and Hahn, S.
(1994)
Genes Dev.
8,
1920-1934[Abstract/Free Full Text]
|
| 53.
|
Van Der Knaap, J. A.,
Borst, J. W.,
Van Der Vliet, P. C.,
Gentz, R.,
and Timmers, H. T. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11827-11832[Abstract/Free Full Text]
|
| 54.
|
Chicca, J. J.,
Auble, D. T.,
and Pugh, B. F.
(1998)
Mol. Cell. Biol.
18,
1701-1710[Abstract/Free Full Text]
|
| 55.
|
Felsenfeld, G.
(1996)
Cell
86,
13-19[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Felsenfeld, G.,
Boyes, J.,
Chung, J.,
Clark, D.,
and Studitsky, V.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9384-9388[Abstract/Free Full Text]
|
| 57.
|
Svaren, J.,
and Horz, W.
(1997)
Trends Biochem. Sci.
22,
93-97 |